Under the partnership, PathomIQ’s AI-based prognostic and predictive biomarkers will be available as a lab developed test in Neuberg Diagnostic's laboratories to help advance precision medicine
PathomIQ and Neuberg Diagnostics plan to make the PATHOMIQ_PRAD test clinically available initially in the US. (Credit: CDC on Unsplash)
US-based PathomIQ and laboratory services provider Neuberg Diagnostics have entered into a multi-year partnership to deploy the former’s PATHOMIQ_PRAD test in the latter’s global network of laboratories.
Under the partnership, PathomIQ’s artificial intelligence (AI)-based prognostic and predictive biomarkers will be available as a lab developed test (LDT) in Neuberg Diagnostic’s laboratories to help advance precision medicine.
The PATHOMIQ_PRAD test is designed to detect patients with organ-localised prostate cancer. The patients are those who would return to the clinic with recurring and/or metastatic disease within a short span of time after prostate surgery and would benefit from adjuvant therapy like salvage radiation therapy and/or androgen deprivation therapy (ADT).
The lab developed test version will be available initially in the US and then in other labs all over the world.
Neuberg Diagnostics executive director Sandip Shah said: “Our mission is to provide cost-effective and best-in-class technologies in clinical laboratory services and make them accessible to people worldwide. We strongly believe AI has the power to democratise cancer care and make it more precise and affordable.
“We are excited to collaborate with PathomIQ to deliver cutting-edge AI solutions such as PATHOMIQ_PRAD that can transform patient care. This is the first of many to come.”
PathomIQ offers AI-based tools for breast, prostate, lung, and other cancers to enable precision medicine by extracting untapped information from digitised haematoxylin and eosin (H&E) histopathology slide images.
The tools use AI to collect prognostic and predictive histologic traits and can identify patients upfront who are most likely to benefit from certain approved and/or investigational therapies.
PathomIQ chief medical officer George Wilding said: “Our PATHOMIQ_PRAD AI model has been successfully validated at multiple medical institutions and pharmaceutical partners, and we are excited to make it clinically available soon through our partnership with Neuberg Diagnostics.”
Neuberg Diagnostics provides molecular and histopathology laboratory services in India, the UAE, South Africa, and the US.